Learn about our research for expanded protection against pneumococcal infections in older adults
About the clinical trial
Today’s vaccines protect against many strains of pneumococcal bacteria, but not all of them. We’re researching an investigational vaccine designed to potentially help expand protection against more bacterial strains and possibly improve the body’s immune response to further reduce rates of infection.
We’re looking for
•Adults 65 to 84 years of age; and
•Have either never received a pneumococcal vaccine or received the PNEUMOVAX® 23 vaccine more than 5 years ago
•Have never been diagnosed with an invasive pneumococcal disease, such as sepsis, pneumonia or meningitis
•Are generally healthy or have stable chronic conditions
What to expect
Participation lasts for about 14 to 18 months and there will be about 9 clinic visits
Participants will be randomly assigned to receive two doses of either the study vaccine with a component to help it potentially work better or a single dose of the study vaccine without the component or Pfizer’s licensed pneumococcal vaccine Prevnar 20® followed by a dose of placebo
There’s no cost to participate and you don’t need insurance to participate. You’ll also be compensated for completing trial-related activities
Taking part in this clinical trial could potentially improve vaccine protection not only for you, but also others in the future.
Ask our team: 786-772-0510
